Form 4: IDEAYA Director Plans Significant Stock Purchase

IDEAYA Biosciences Director Jeffrey Stein reported a planned acquisition of 50,000 shares of common stock on March 2, 2026, at a weighted average price of $32.9578.

Summary

• IDEAYA Biosciences, Inc. Director Jeffrey Stein filed a Form 4 indicating a planned acquisition of 50,000 shares of common stock.
• The transaction is scheduled to occur on March 2, 2026, at a weighted average purchase price of $32.9578 per share.
• The purchase is being made pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up pre-planned trades.
• Following this planned transaction, Jeffrey Stein will directly own 54,281 shares of common stock.
• Additionally, 3,363 shares are indirectly beneficially owned by his son.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. A director's planned purchase of a significant number of shares indicates high confidence in the company's future, which is generally bullish for the stock.

Positives

• The planned acquisition of 50,000 shares by a director signals strong insider confidence in the company's future performance and valuation.
• The transaction is pre-planned under Rule 10b5-1(c), indicating a structured and deliberate investment decision.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the planned transaction date.

Management Comments

• Director Jeffrey Stein's planned purchase of 50,000 shares at a significant price point signals strong confidence in IDEAYA Biosciences' future prospects and valuation.

Industry Context

StockSavvy.ai notes that insider buying, particularly a substantial planned purchase by a director, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its stock is undervalued or poised for growth. This action aligns with a broader trend where strategic insider investments can bolster investor sentiment in the biotechnology sector, which often relies on long-term growth potential.

Comparison to Industry Standards

• Insider purchases, especially those executed under Rule 10b5-1 plans, are a common practice across industries, including biotechnology.
• A purchase of 50,000 shares by a director represents a notable commitment, often exceeding typical open-market purchases by individual executives in companies of similar market capitalization.
• Compared to other biotech firms where insider activity might be more sporadic, a pre-planned, significant buy like this can be seen as a more robust indicator of sustained confidence.

Related Party Transactions

• Jeffrey Stein indirectly beneficially owns 3,363 shares through his son.

Stakeholder Impact

• Shareholders may view this planned insider purchase as a strong vote of confidence from management, potentially increasing investor trust and demand for the stock.

Key Dates

Recommendation

The planned acquisition of 50,000 shares by Director Jeffrey Stein, executed under a Rule 10b5-1 plan, is a significant bullish signal. Insider buying, especially of this magnitude, suggests that a key executive with intimate knowledge of the company's operations and future prospects believes the stock is undervalued or has substantial upside potential. This action warrants a 'buy' recommendation for investors looking for companies with strong internal conviction.

Keywords

IDEAYA Biosciences, IDYA, Insider Buying, Form 4, Jeffrey Stein, Stock Purchase, Biotechnology, Director Transaction, 10b5-1 Plan